Truist Securities Rates Insulet (PODD) buy, $219 Price Target
Truist Securities reiterates its buy rating for Insulet Corporation with a new price target of $219, a 52.59% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Truist Securities rated Insulet Corporation ($PODD) "buy" with a $219 price target on June 12, 2026.
Since the rating, $PODD is down 7.2% after 1 week, up 8.3% after 1 month and down 5.7% to date (from the $149.70 close on Jun 12, 2026).
PODD
Insulet Corporation
Key Points
- Truist Securities has reiterated its buy rating on Insulet Corporation, raising the price target to $219 from a previous estimate.
- Insulet's shares recently traded at $143.52, significantly below the new target price, indicating potential upside.
- The company is set to report earnings on November 5, 2026, following a revenue growth of 23.5% in its latest financial results.
Get $PODD trade alerts by text
We text you when insiders, Congress or big funds trade $PODD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Insulet Corporation alert may contain errors. Disclosures
Truist Securities Reiterates Buy Rating
Truist Securities has reiterated its buy rating on Insulet Corporation (PODD), setting a new price target of $219. This update came on June 12, 2026, as the shares were trading at $143.52. The previous target was not available, but this new estimate reflects a more optimistic outlook for the company.
Analysts Set New Price Targets
Truist's decision comes amid a mix of analyst opinions on Insulet. For instance, Jefferies maintains a buy rating with a target of $190, while Canaccord Genuity also keeps a buy rating but lowers its target to $179. Meanwhile, Barclays initiated coverage with an equal-weight rating and a target of $150. The consensus among analysts shows a general bullish sentiment, with the average target price sitting at approximately $171.91.
Stock Performance Context
Insulet's shares are currently trading at $143.52, which is well below the 52-week high of $354.88. This price point suggests that the stock may have room to grow, especially with a significant target of $219 set by Truist. The shares are also trading below their 50-day moving average of $150.25 and 200-day average of $200.82, indicating potential volatility and opportunity for future gains.
$PODD price target
Insulet Corporation daily closes and this analyst's $219 target. Not advice.
What Insulet Corporation Does
Insulet Corporation develops and sells insulin delivery systems for people with diabetes. Its flagship products include the Omnipod platform, which offers automated insulin delivery solutions. The company has a strong market presence, particularly in the U.S. and international markets, making it a key player in the medical devices sector.
What's Ahead for Insulet Corporation
Investors should keep an eye on Insulet's upcoming earnings report on November 5, 2026. The reiterated rating from Truist Securities may influence market sentiment as more analysts weigh in on the company's performance and outlook. As always, the latest 13F filings will provide insights into institutional investors' positions in the company.
Related Filing Alerts
Source: Truist Securities's rating change on $PODD (Jun 12, 2026). Written by software, not financial advice. How we make alerts